If you developed serious health complications while taking type 2 diabetes medication Onglyza (saxagliptin), you’re not alone. Reported Onglyza adverse reactions range from heart failure to pancreatic cancer and even death. In 2013, two large clinical trials found DPP-4 inhibitor drugs like Onglyza and Kombiglyze XR can lead to heart failure. But it wasn’t until 2014 that the Food and Drug Administration required Onglyza’s manufacturer, AstraZeneca, to update Onglyza’s warning label. As a result, any type 2 diabetics suffering from heart failure or pancreatitis may file an Onglyza claim against AstraZeneca. If you’re considering filing an Onglyza claim to get the justice you deserve, here’s what you need to know.

Who Is Eligible to File An Onglyza Claim?

Attorneys nationwide are accepting claims from individuals who experienced a cardiovascular event while taking Onglyza or Kombiglyze® XR. Serious adverse events may include heart failure, congestive heart failure, cardiac arrest, pancreatitis or pancreatic cancer. Further, victims’ families may choose to file a wrongful death Onglyza claim on a deceased relative’s behalf. In addition, individuals taking other DPP-4 inhibitors which are chemically similar to saxagliptin may also qualify for an Onglyza claim. These drugs include:

• Kombiglyze XR (saxagliptin and extended-release metformin HCL)
• Glyxambi® (empagliflozin and linagliptin)
• Tradjenta® (linagliptin)
• Oseni (alogliptin and pioglitazone)
• Januvia® (sitagliptin)
• Nesina (alogliptin)
• Kazano (alogliptin and metformin)

For more details about the link between DPP-4 inhibitors and heart failure, see the FDA’s April 2016 drug safety communication.

How An Attorney Can Help With Your Onglyza Claim

Having an attorney represent your Onglyza claim can help you get the most financial compensation you’re rightfully owed in court. An experienced attorney can show evidence that AstraZeneca failed to conduct FDA-recommended heart risk safety testing before Onglyza’s 2009 approval. Since AstraZeneca touted benefits (like not gaining weight) and downplayed risks, you may file a “failure to warn” Onglyza claim.
Nearly every pending Onglyza claim alleges AstraZeneca failed to properly warn consumers about its potential heart failure and death risks. Plaintiffs also allege AstraZeneca didn’t conduct adequate pre-market research regarding the drug’s long-term complication risks. Since the statute of limitations regarding pharmaceutical litigation varies by state, file your Onglyza claim as soon as possible. Any delay in filing your Onglyza claim could exclude you from obtaining the financial compensation you deserve through a settlement.

Current Onglyza Claim Litigation Status and Settlement Outlook

Although multiple Onglyza and Kombiglyza XR lawsuits are underway against AstraZeneca, none have yet been settled. However, experts believe current Onglyza litigation could follow a similar pattern to Invokana — another potentially dangerous type 2 diabetes medication. A New Jersey district judge recently consolidated all Invokana lawsuits under one multidistrict litigation (MDL). These bellwether trials will influence future pharmaceutical claims and may spur Invokana’s manufacturer, Janssen Pharmaceuticals, to settle out of court. In other words, the Invokana MDL could result in a hefty cash settlement for all plaintiffs involved.

Get Your Free Onglyza Claim Review In Just Minutes

If you or a loved one experienced heart problems or pancreatitis while taking Onglyza, you may qualify for financial compensation. To see if you may have an eligible claim, fill out your free Onglyza case evaluation form today. An experienced pharmaceutical attorney in your area will call to discuss compensation options and next steps for your Onglyza claim.